Wisdom approves FDA listing for Guardant360Liquid CDx
The U.S. Food and Drug Administration has approved the Guardant360® Liquid CDx test, the largest approved liquid biopsy for detecting cancer-related genomic mutations from a simple blood sample, helping physicians make precise treatment decisions for patients with advanced cancer. The test features broader genomic coverage and increased detection sensitivity compared to the previous version. It is currently used in the diagnosis of non-small cell lung cancer, colorectal cancer, and advanced breast cancer. This approval underscores advancements in precision diagnostics and accelerates test results, which are now available in just seven days.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)